Investor Presentaiton
1H20
Performance
A strong half year for CSL
with revenue up 11%¹ and
net profit after tax up 11%¹
reflecting:
•
Strong growth in
immunoglobulin portfolio
• Transition to own distribution
model in China progressing
well
•
•
Continued evolution of the
haemophilia portfolio
Strong performance from
Seqirus
CSL BEHRING
PRIVIGENⓇ +28%1
HIZENTRA® +37%¹
• ALBUMIN -33%1 (GSP IMPACT)
AFSTYLAⓇ +30%¹
IDELVION® +21%1
ZEMAIRA® +31%1
SEQIRUS
·
Seasonal influenza +16%1
.
FLUCELVAXⓇ launched in EU
FLUADⓇ preferred recommendations
in UK & Australia
.
Positive real world effectiveness
evidence continuing
Commenced aQIVc development
12 Driven by Our Promise™
1. Growth percentages shown at constant currency to remove the impact of exchange rate movements,
facilitating comparability of operational performance. See end note for further detail.View entire presentation